Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Macrogenics
(NQ:
MGNX
)
3.870
+0.210 (+5.74%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Macrogenics
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
MacroGenics Shares Tumble After Reporting Adverse Events, Multiple Deaths In Cancer Drug Trial
May 10, 2024
Latest interim data from TAMARACK Phase 2 study by MacroGenics unveils insights into vobramitamab duocarmazine targeting B7-H3 in metastatic prostate cancer. Despite responses, notable safety concerns...
Via
Benzinga
Topics
Death
Exposures
Death
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against MacroGenics, Inc. and Encourages Investors to Contact the Firm
May 10, 2024
From
Schall Law
Via
GlobeNewswire
Dow Jumps Over 100 Points; DNOW Posts Downbeat Earnings
May 10, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Is Progyny (PGNY) Stock Down 27% Today?
May 10, 2024
Progyny stock is down on Friday after the company posted a revenue miss for Q1 and disappointed PGNY investors with its guidance!
Via
InvestorPlace
The Latest Analyst Ratings For Macrogenics
April 04, 2024
Via
Benzinga
MacroGenics Inc. (NASDAQ: MGNX) Leading the Way in Thursday Trading Based on Percentage Gain
April 04, 2024
Via
Investor Brand Network
Macrogenics: Q4 Earnings Insights
March 07, 2024
Via
Benzinga
Why Natera Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
May 10, 2024
Via
Benzinga
Why Is Macrogenics (MGNX) Stock Down 69% Today?
May 10, 2024
Macrogenics stock is down on Friday as MGNX investors react to clinical trial deaths and missed earnings for the first quarter of 2024.
Via
InvestorPlace
Topics
Death
Exposures
Death
12 Health Care Stocks Moving In Friday's Pre-Market Session
May 10, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
May 10, 2024
The biggest pre-market stock movers are ready to go as we check out all of the hottest news happening on Friday morning!
Via
InvestorPlace
A Preview Of Macrogenics's Earnings
March 06, 2024
Via
Benzinga
MacroGenics Inc. (NASDAQ: MGNX) is a Stock Spotlight on 3/5
March 05, 2024
Via
Investor Brand Network
Analyst Expectations For Macrogenics's Future
March 04, 2024
Via
Benzinga
Akamai Technologies Issues Weak Outlook, Joins Applied Optoelectronics, JFrog And Other Big Stocks Moving Lower In Friday's Pre-Market Session
May 10, 2024
Via
Benzinga
MacroGenics (MGNX) Q1 2024 Earnings Call Transcript
May 10, 2024
MGNX earnings call for the period ending March 31, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
MGNX Stock Earnings: Macrogenics Misses EPS, Misses Revenue for Q1 2024
May 09, 2024
MGNX stock results show that Macrogenics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
May 09, 2024
Via
Benzinga
MacroGenics Announces Date of First Quarter 2024 Financial Results Conference Call
May 03, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
Masters In Trading - Saturday, April 27
April 27, 2024
In this recap of the most recent trading session, I review my portfolio and share one of the trades taken this week.
Via
Talk Markets
Look Out For These 6 Stocks As Analysts Predicts Major Gains, One Up To 82%
April 05, 2024
Investment analysts have revised their price targets upwards for six major stocks this week, with one company expected to see an 82% surge. The revised targets include four U.S.-listed companies, with...
Via
Benzinga
MacroGenics Analyst Impressed By Improved Safety Profile From Prostate Cancer Candidate
April 04, 2024
Update on MacroGenics Inc's Phase 2 TAMARACK study of vobramitamab duocarmazine (vobra duo) for metastatic castration-resistant prostate cancer (mCRPC). Safety and preliminary efficacy data anticipated...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
April 04, 2024
Via
Benzinga
Simulations Plus Posts Upbeat, Joins Levi Strauss, BlackBerry And Other Big Stocks Moving Higher In Thursday's Pre-Market Session
April 04, 2024
U.S. stock futures were higher this morning, with the Dow futures gaining by around 90 points on Thursday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
April 04, 2024
Shares of STAAR Surgical Company (NASDAQ: STAA) rose sharply during Thursday’s session after the company issued strong preliminary first-quarter net sales guidance. STAAR Surgical shares jumped 13.3%...
Via
Benzinga
MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures
April 03, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
MacroGenics (MGNX) Q4 2023 Earnings Call Transcript
March 08, 2024
MGNX earnings call for the period ending December 31, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
MGNX Stock Earnings: Macrogenics Misses EPS for Q4 2023
March 07, 2024
MGNX stock results show that Macrogenics missed analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
March 07, 2024
Via
Benzinga
Earnings Scheduled For March 7, 2024
March 07, 2024
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.